United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 2 minute read Pharma Industry News FDA rejects Correvio Pharma’s anti-arrhythmic drug Brinavess Correvio Pharma said that the US Food and Drug Administration (FDA) decided not to approve its anti-arrhythmic drug… bypharmanewsdailyDecember 25, 2019
